~~<i id='91D04A1E85'><strike id='91D04A1E85'><tt id='91D04A1E85'><pre id='91D04A1E85'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：leisure time 2025-09-30 13:02:08 Page View：18

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Election results set back Medicaid expansion plans
Next article： The high cost of giving birth even with insurance

comprehensive

Bright Health sells Medicare Advantage business to Molina

BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

Feed a cold, starve a fever? Here’s what science says

MatthewMead/AP“Feedacold,starveafever”isanadagethathasbeenaroundforcenturies.Nowanewstudyinmicefinds

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

With heat waves through August, officials warn of health risks

Analreadyrecord-settingsummerheatwavewillcontinuethroughAugustandwillputmorethan51millionAmericansat